Hospital General Universitario Gregorio Marañón-ko ikertzaileekin lankidetzan egindako argitalpenak (19)

2024

  1. Survival after allogeneic transplantation according to pretransplant minimal residual disease and conditioning intensity in patients with acute myeloid leukemia

    Frontiers in Oncology, Vol. 14

2023

  1. Impact of the COVID-19 pandemic on the diagnosis and treatment of onco-hematologic patients: a discussion paper

    Revista Espanola de Quimioterapia, Vol. 36, Núm. 1, pp. 1-25

  2. Philadelphia-negative chronic myeloproliferative neoplasm follow-up: when the phone rings. Changes during the COVID-19 pandemic and patient satisfaction. Experience in 30 health centers in Spain

    Annals of Hematology, Vol. 102, Núm. 2, pp. 447-456

  3. Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors

    Cancers, Vol. 15, Núm. 4

2022

  1. Breakthrough infections in MPN-COVID vaccinated patients

    Blood Cancer Journal

  2. Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID-19

    American Journal of Hematology

  3. Second versus first wave of COVID-19 in patients with MPN

    Leukemia

2021

  1. Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19

    Blood Cancer Journal, Vol. 11, Núm. 2

  2. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib

    Leukemia, Vol. 35, Núm. 2, pp. 485-493

  3. Long-term follow-up of recovered MPN patients with COVID-19

    Blood Cancer Journal

2020

  1. Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model

    Biology of Blood and Marrow Transplantation, Vol. 26, Núm. 12, pp. 2237-2244

2018

  1. Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?

    Annals of Hematology, Vol. 97, Núm. 11, pp. 2089-2098

  2. Feasibility of treatment discontinuation in chronic myeloid leukemia in clinical practice: results from a nationwide series of 236 patients

    Blood Cancer Journal, Vol. 8, Núm. 10

2017

  1. A BCR-ABL1 cutoff of 1.5% at 3 months, determined by the GeneXpert system, predicts an optimal response in patients with chronic myeloid leukemia

    PLoS ONE, Vol. 12, Núm. 3

  2. Imatinib dose reduction in patients with chronic myeloid leukemia in sustained deep molecular response

    Annals of Hematology, Vol. 96, Núm. 1, pp. 81-85

2016

  1. Leucemia mieloide crónica en España: sus características de presentación han cambiado. Sección española del registro poblacional EUTOS

    Revista Clinica Espanola, Vol. 216, Núm. 6, pp. 293-300

2015

  1. Bosutinib shows low cross intolerance, in chronic myeloid leukemia patients treated in fourth line. Results of the Spanish compassionate use program

    American Journal of Hematology, Vol. 90, Núm. 5, pp. 429-433

  2. Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months

    Cancer Medicine, Vol. 4, Núm. 7, pp. 995-1002

2014

  1. Do chronic myeloid leukemia patients with late “warning” responses benefit from “watch and wait” or switching therapy to a second generation tyrosine kinase inhibitor?

    American Journal of Hematology, Vol. 89, Núm. 11, pp. E206-E211